Insulin injection pen

Abstract

The insulin injection pen comprises an injector body, an injection assembly and a limiting mechanism, the injector body comprises an opening, the opening is formed in one end of the injector body, the injection assembly comprises a needle seat and a needle tube, the needle seat comprises a containing cavity, the needle seat is inserted in the opening so that the needle tube can be conveniently installed, one end of the needle tube is connected with the needle seat, and the limiting mechanism is arranged on the needle tube. And the cavity is communicated with the accommodating cavity. According to the insulin injection pen, due to the adoption of the technical means of the limiting mechanism, when the insulin injection pen is in a working state, the limiting piece enables the needle seat to be firmly connected with the injector main body, the stability and accuracy of the injection process are ensured, and in a non-working state, the limiting piece is separated from the main body, so that the needle seat is convenient to disassemble and treat. According to the technical scheme, the problems that an existing injection pen needle is complex to disassemble and large in potential safety hazard are effectively solved, operation simplicity and use safety are improved, and then automation, convenience and safety of the insulin injection pen are achieved.

Description

Technical Field

[0001] This utility model relates to an injection pen, and more particularly to an insulin injection pen. Background Technology

[0002] An insulin pen is an important medical device used by diabetic patients to manage their insulin dosage. Due to its portability, ease of use, and adjustable dosage, the insulin pen has gradually replaced traditional syringes and become the mainstream tool in diabetes treatment. Modern insulin pens not only improve patient adherence but also help patients effectively manage their blood sugar levels by precisely controlling the insulin dosage.

[0003] Existing insulin pens typically consist of a syringe body and an injection assembly. The syringe body includes a drug reservoir and a dosage setting device, allowing users to adjust the injection dose as needed. The injection assembly includes a needle hub and a needle tube; the needle hub secures the needle, ensuring stability and accuracy during injection. During use, the needle needs to be firmly connected to the syringe body to guarantee accurate insulin injection. In existing designs, the needle needs to be manually rotated or detached from the syringe body after injection. This process usually requires manual intervention from the user to ensure safe disposal of the needle and reuse of the device.

[0004] However, the manual rotation or removal of the needle is cumbersome, increasing the complexity of user operation, especially for patients with poor eyesight or hand dexterity, making it difficult to use. Secondly, existing designs lack effective needle protection, increasing the risk of needlestick injuries during disassembly, posing a safety hazard. These problems not only reduce the convenience and safety of insulin pen use but also increase potential risks during medical procedures. Therefore, there is an urgent need to develop an insulin pen that addresses these issues. Utility Model Content

[0005] The purpose of this invention is to provide an insulin pen that can automatically separate and connect the injection component and the syringe body through a limiting mechanism.

[0006] The technical solution adopted by this utility model to solve the above problems is: an insulin injection pen, comprising:

[0007] The syringe body, including the opening.

[0008] Injection assembly, including:

[0009] A needle hub, including a receiving cavity, wherein the needle hub is inserted into the opening.

[0010] A needle tube, one end of which is connected to the needle hub, and the needle tube communicates with the accommodating cavity.

[0011] The limiting mechanism includes:

[0012] A limiting member is provided at the opening, and the limiting member is movable in a controlled manner.

[0013] When the insulin pen is in operation, the limiting member is connected to the needle hub, so that the needle hub is connected to the syringe body, confining the injection assembly at the opening of the syringe body. When the insulin pen is not in operation, the limiting member is separated from the syringe body.

[0014] Preferably, the limiting mechanism further includes a connector, which is disposed at the opening and has a moving channel on the inner wall facing the needle seat.

[0015] The outer surface of the needle holder has a receiving groove facing the inner wall of the opening.

[0016] The limiting member is disposed within the moving channel, and the limiting member includes a limiting end, which is disposed toward the needle seat.

[0017] When the insulin pen is in operation, the limiting end of the limiting member engages with the receiving groove on the outer surface of the needle hub. When the insulin pen is not in operation, the limiting end of the limiting member disengages from the receiving groove.

[0018] Preferably, the limiting member is a magnetically conductive member.

[0019] The limiting mechanism further includes:

[0020] An elastic element is disposed within the moving channel. One end of the elastic element abuts against the inner wall of the moving channel, and the other end of the elastic element abuts against the limiting element, so as to provide elastic force to the limiting element toward the needle seat, and so that the limiting end of the limiting element is exposed in the opening.

[0021] A magnetic force generating component is disposed on the side of the connector away from the needle hub, and the position of the magnetic force generating component is opposite to the limiting member, so as to apply a magnetic attraction force away from the needle hub to the limiting member when the insulin pen is in a non-working state, so as to separate the limiting end from the receiving groove.

[0022] Preferably, the end of the limiting member opposite to the needle seat is provided with a magnetic element.

[0023] The limiting mechanism further includes:

[0024] A magnetic force generating component is disposed on the side of the connector away from the needle seat. The magnetic pole position of the magnetic force generating component is oriented opposite to the magnetic element at the end of the limiting member, and the magnetic pole direction of the magnetic force generating component is controlled to change.

[0025] When the insulin pen is not in operation, the magnetic pole of the magnetic force generating component facing the needle hub is opposite to the magnetic pole of the magnetic element facing away from the needle hub, thereby applying a magnetic attraction force to the magnetic element and causing the limiting end of the limiting member to separate from the receiving groove. When the insulin pen is in operation, the magnetic pole of the magnetic force generating component facing the needle hub is the same as the magnetic pole of the magnetic element facing away from the needle hub, thereby applying a repulsive force to the magnetic element and causing the limiting end of the limiting member to engage with the receiving groove.

[0026] Preferably, the limiting component further includes:

[0027] A drive assembly, including a controllable rotating drive end, is disposed at the opening of the syringe body, and the drive end is connected to the connector to drive the connector to rotate around the needle hub.

[0028] Preferably, the driving component further includes:

[0029] A stator is disposed at the opening in the syringe body.

[0030] The rotor is connected to the stator in a controlled rotation manner, and the driving end is the end of the rotor that is away from the stator.

[0031] Preferably, the insulin pen further includes:

[0032] A drug storage container, the drug storage container including a liquid storage cavity and a drug outlet communicating with the liquid storage cavity.

[0033] The syringe body also includes a receiving space communicating with the opening, the drug storage container is disposed in the receiving space, the drug outlet is inserted into the opening, and the needle hub is inserted into the drug outlet.

[0034] Preferably, the inner wall of the drug outlet is constructed as a first conical surface, and the outer periphery of the insertion portion of the needle seat and the drug outlet is constructed as a second conical surface that matches the first conical surface of the inner wall of the drug outlet.

[0035] Preferably, a gap is provided between the side of the needle holder facing the connector and the side of the connector facing the needle holder.

[0036] Beneficial effects of the embodiments of this utility model

[0037] This insulin pen employs a limiting mechanism that securely connects the needle hub to the syringe body when the pen is in operation, ensuring stability and accuracy during injection. When not in operation, the limiting mechanism detaches, facilitating needle hub disassembly and disposal. This technology effectively solves the problems of complex needle disassembly and significant safety hazards associated with existing insulin pen needles, improving ease of operation and safety, thereby achieving automation, convenience, and safety in insulin pen injection.

[0038] On the one hand, this insulin pen employs a magnetically conductive limiting component, an elastic component, and a magnetic force generating component. The elastic component provides continuous elastic force to the limiting component, allowing the limiting end to engage with the needle holder's receiving groove during operation, thus ensuring the connection between the needle holder and the syringe body. In the non-operating state, the magnetic force generating component applies a magnetic attraction force to the limiting component, separating it from the receiving groove. This design effectively solves the problems of cumbersome needle disassembly and unreliable limiting in existing technologies, improving operational convenience and safety.

[0039] Furthermore, this insulin pen employs a limiting component, an elastic component, a magnetic force generating component, and a drive component. The elastic force provided by the elastic component allows the limiting end of the limiting component to engage with the needle holder groove during operation, ensuring a stable connection to the needle holder. In the non-operating state, the magnetic force generating component applies magnetic attraction, separating the limiting component from the groove for easy needle disassembly. The drive component controls the rotation of the rotor relative to the stator, enabling controlled movement of the connecting component to align the limiting end with the groove and engage it. This enhances the automated control capability of the limiting mechanism and significantly improves operational convenience.

[0040] On the other hand, this insulin pen, by employing a limiting component, a magnetic component, a receiving groove, and a magnetic force generating component, achieves automatic movement of the limiting component in both working and non-working states through controllable switching of the magnetic pole direction. In the non-working state, the magnetic force generating component applies a magnetic attraction force to separate the limiting component from the needle hub; in the working state, a repulsive force is applied to engage the limiting component with the needle hub. This design effectively solves the problems of complex needle disassembly and unreliable limiting in existing technologies, significantly improving the convenience and safety of operation.

[0041] Furthermore, this insulin pen employs technologies such as a limiting component, a magnetic component, a magnetic force generating assembly, and a driving assembly. Through magnetic pole direction reversal and controlled rotation of the driving assembly, it achieves automatic movement and engagement / disengagement of the limiting component. The rotor and stator in the driving assembly cooperate to allow the connector to rotate around the needle holder. The driving assembly controls the controlled movement of the connector through the rotation of the rotor relative to the stator, thereby controlling the limiting end to move to the receiving groove for alignment and engagement, further improving the operational reliability and automated control capability of the limiting mechanism. Attached Figure Description

[0042] Figure 1 This is a schematic structural diagram of an insulin injection pen according to one embodiment of the present invention.

[0043] Figure 2 This is a partial cross-sectional view of the injection component of an insulin pen in one embodiment of the present invention. Figure 1 .

[0044] Figure 3 This is a partial cross-sectional view of the injection component of an insulin pen in one embodiment of the present invention. Figure 2 .

[0045] Figure 4 This is a schematic exploded view of an insulin injection pen according to one embodiment of the present invention.

[0046] Figure 5 This is a schematic exploded view of the injection component, the limiting component, and the drug storage container in one embodiment of the present invention.

[0047] Wherein: 100, syringe body; 110, opening; 120, accommodating space; 200, injection assembly; 210, needle hub; 211, accommodating cavity; 212, second conical surface; 213, accommodating groove; 220, needle tube; 300, limiting mechanism; 310, limiting component; 311, limiting end; 320, connecting component; 321, moving channel; 330, elastic component; 340, magnetic force generating assembly; 350, magnetic component; 360, driving assembly; 361, stator; 362, rotor; 3621, driving end; 370, housing; 371, base; 372, rotating body; 400, drug storage container; 410, liquid storage cavity; 420, drug outlet; 421, first conical surface; 500, button. Detailed Implementation

[0048] The following embodiments are used to illustrate the present invention, but are not intended to limit the scope of the present invention.

[0049] In the description of this application, it should be understood that the terms "center," "longitudinal," "lateral," "upper," "lower," "front," "rear," "left," "right," "vertical," "horizontal," "top," "bottom," "inner," and "outer," etc., indicating orientation or positional relationships based on the orientation or positional relationships shown in the accompanying drawings, are used only for the convenience of describing this application and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, or be constructed and operated in a specific orientation, and therefore should not be construed as limiting the scope of protection of this application. Furthermore, the terms "first," "second," etc., are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of indicated technical features. Thus, features defined with "first," "second," etc., may explicitly or implicitly include one or more of that feature. In the description of this application, unless otherwise stated, "a plurality of" means two or more.

[0050] In the description of this application, it should be noted that, unless otherwise expressly specified and limited, the terms "installation," "connection," and "linking" should be interpreted broadly. For example, they can refer to a fixed connection, a detachable connection, or an integral connection; they can refer to a mechanical connection or an electrical connection; they can refer to a direct connection or an indirect connection through an intermediate medium; and they can refer to the internal connection between two components. Those skilled in the art will understand the specific meaning of the above terms in this application based on the specific circumstances.

[0051] This application provides a novel insulin injection pen that solves the problems of complex needle disassembly, inconvenient operation, and the risk of needlestick injury in the prior art.

[0052] This technical solution employs a limiting mechanism 300 to engage the limiting member 310 with the needle holder 210 when the injection pen is in operation, ensuring a stable connection between the needle holder 210 and the syringe body 100. In the non-operating state, the limiting member 310 separates from the needle holder 210 through magnetic and elastic forces, facilitating needle removal.

[0053] This solution improves the ease of operation and safety of insulin injection pens, effectively overcoming the problems of complicated needle disassembly, needlestick injury risk, and inconvenience in operation of existing insulin injection pens.

[0054] To better understand the above technical solutions, the following will provide a detailed explanation of the technical solutions in conjunction with the accompanying drawings and specific implementation methods.

[0055] See Figures 1 to 3This application discloses a preferred embodiment of an insulin pen, including a syringe body 100, an injection assembly 200, and a limiting mechanism 300. The syringe body 100 includes an opening 110 located at one end. The injection assembly 200 includes a needle hub 210 and a needle tube 220. The needle hub 210 includes a receiving cavity 211 and is inserted into the opening 110 to accommodate the needle tube 220. One end of the needle tube 220 is connected to the needle hub 210 and communicates with the receiving cavity 211, guiding insulin to the injection target through the needle hub 210. The limiting mechanism 300 includes a limiting member 310 located at the opening 110. The limiting member 310 is controllable in movement to adjust its position according to usage requirements.

[0056] Specifically, the opening 110 is designed as one end of the syringe body 100, typically a hollow cylinder, for mounting and securing the needle hub 210. The needle hub 210 is an approximately cylindrical structure, and its dimensions are adapted to the opening 110. One end of the needle hub 210 is open to insert into the opening 110 and connects to the syringe body 100 via a direct push-in method. The needle tube 220 is a slender tubular structure used to deliver insulin to the injection target. The connecting end of the needle tube 220 typically has a tapered or specifically shaped interface to ensure a sealed connection with the receiving cavity 211. A limiting member 310 is located at the opening 110 and is a movable component, typically including a push-pull rod, knob, or other mechanical operating parts. The limiting member 310 can move axially along the syringe body 100 or lock and unlock the needle hub 210 by rotation or other means.

[0057] When the insulin pen is in operation, the limiting member 310 is connected to the needle hub 210 via a simple mechanical connection. This connection ensures that the needle hub 210 is fixed to the syringe body 100, thereby securely restraining the injection assembly 200 at the opening 110 of the syringe body 100. This connection can be achieved by rotating or pushing / pulling the limiting member 310.

[0058] When the insulin pen is not in use, the limiting member 310 can be separated from the syringe body 100 by the same rotation or push-pull operation, which makes it easy to replace the needle 220 or to clean and maintain the pen.

[0059] In actual operation, users can easily switch the insulin pen's working and non-working states by operating the limiting member 310. This design not only ensures safety but also improves ease of use. For example, when the needle 220 needs to be replaced, the user can easily separate the limiting member 310 from the syringe body 100, replace the needle 220, and then operate the limiting member 310 again to reconnect it to the needle hub 210, completing the needle 220 replacement.

[0060] This embodiment simplifies the operation process, allowing users to prepare and maintain insulin pens more quickly and safely, while ensuring the stability and reliability of components during injection.

[0061] For further information, please refer to [link / reference]. Figures 4 to 5 The limiting mechanism 300 further includes a connector 320, which is disposed at the opening 110. The connector 320 has a moving channel 321 on its inner wall facing the needle holder 210. The outer surface of the needle holder 210 has a receiving groove 213 facing the inner wall of the opening 110. The limiting member 310 is disposed within the moving channel 321 and includes a limiting end 311, which is oriented towards the needle holder 210. When the insulin pen is in working condition, the limiting end 311 of the limiting member 310 engages with the receiving groove 213 on the outer surface of the needle holder 210; when the insulin pen is not in working condition, the limiting end 311 of the limiting member 310 disengages from the receiving groove 213.

[0062] Specifically, the connector 320 is located at the opening 110, and a moving channel 321 is formed on its inner wall facing the needle holder 210. The connector 320 is typically an annular structure, with its inner wall tightly fitting against the outer surface of the opening 110 to ensure stability, and provides the moving channel 321 for placing and guiding the limiting member 310. A receiving groove 213 is formed on the outer surface of the needle holder 210 facing the inner wall of the opening 110. The limiting member 310 is located within the moving channel 321. The limiting member 310 is typically an elongated structure, with its limiting end 311 designed as a protrusion facing the needle holder 210. The limiting member 310 can slide axially within the moving channel 321, engaging or disengaging from the receiving groove 213 via an internal spring or other mechanical mechanism.

[0063] When the insulin pen is in operation, the limiting end 311 of the limiting member 310 engages with the receiving groove 213 on the outer surface of the needle hub 210. This engagement is triggered by the user operating the limiting member 310 (e.g., pushing, pulling, or rotating), ensuring the connection stability between the needle hub 210 and the syringe body 100, thereby providing the necessary fixation during injection.

[0064] When the insulin pen is not in use, the user performs the reverse operation to separate the limiting end 311 of the limiting member 310 from the receiving groove 213. This design allows the needle hub 210 to be easily removed from the syringe body 100, facilitating the replacement of the needle tube 220 or cleaning and maintenance.

[0065] This structural and connection design not only improves the operational efficiency and safety of the insulin pen, but also ensures the stability and reliability of the components during injection through precise mechanical control, meeting the high standards required for clinical and personal use.

[0066] In some embodiments, please refer to Figure 2 The limiting member 310 is a magnetically conductive element. The limiting mechanism 300 also includes an elastic member 330 and a magnetic force generating assembly 340. The elastic member 330 is disposed within the moving channel 321, with one end abutting against the inner wall of the moving channel 321 and the other end abutting against the limiting member 310, providing elastic force to the limiting member 310 toward the needle holder 210, so that the limiting end 311 of the limiting member 310 is exposed in the opening 110. The magnetic force generating assembly 340 is disposed on the side of the connecting member 320 away from the needle holder 210, and the position of the magnetic force generating assembly 340 is opposite to the limiting member 310, so that when the insulin pen is in a non-working state, it applies a magnetic attraction force away from the needle holder 210 to the limiting member 310, causing the limiting end 311 to separate from the receiving groove 213.

[0067] Specifically, the limiting member 310 is a magnetically conductive component, disposed within the moving channel 321, and includes a limiting end 311. The limiting member 310 is an elongated magnetic structure, with the limiting end 311 designed as a protrusion facing the needle holder 210. The limiting member 310 can slide axially within the moving channel 321, engaging or disengaging with the receiving groove 213 through internal magnetic force or mechanical mechanism. The elastic member 330 is disposed within the moving channel 321, with one end abutting against the inner wall of the moving channel 321 and the other end abutting against the limiting member 310. The elastic member 330 is typically a spring, providing the necessary elasticity to expose the limiting end 311 of the limiting member 310 in the opening 110, ensuring that the limiting end 311 can stably engage with the receiving groove 213 during operation. The magnetic force generating assembly 340 is disposed on the side of the connecting member 320 away from the needle holder 210, and is oriented opposite to the limiting member 310. When the insulin pen is not in operation, the magnetic force generating component 340 applies a magnetic attraction force away from the needle holder 210. This magnetic force is sufficient to separate the limiting end 311 of the limiting member 310 from the receiving groove 213, making it easier to replace or clean the needle 220.

[0068] When the insulin pen is in operation, the limiting end 311 of the limiting member 310 engages with the receiving groove 213 on the outer surface of the needle holder 210. Through the interaction of the elastic force of the elastic member 330 and the magnetic attraction force of the magnetic force generating component 340, the connection stability between the needle holder 210 and the syringe body 100 is ensured, thereby providing the necessary fixation during the injection process.

[0069] When the insulin pen is not in use, the magnetic attraction of the magnetic force generating component 340 guides the movement of the limiting member 310, causing the limiting end 311 to separate from the receiving groove 213. This design allows the needle hub 210 to be easily removed from the syringe body 100, facilitating the replacement of the needle tube 220 or cleaning and maintenance.

[0070] This embodiment combines mechanical and magnetic technologies to ensure ease of operation and safety, while improving the reliability and maintenance efficiency of the insulin pen.

[0071] In other embodiments, see Figure 3 The limiting member 310 has a magnetic element 350 at one end opposite to the needle holder 210. The limiting mechanism 300 also includes a magnetic force generating component 340, which is disposed on the side of the connecting member 320 opposite to the needle holder 210. The magnetic poles of the magnetic force generating component 340 are positioned opposite to the magnetic element 350 at the end of the limiting member 310, and the direction of the magnetic poles of the magnetic force generating component 340 is controllably switched. Specifically, when the insulin pen is not in operation, the magnetic poles of the magnetic force generating component 340 facing the needle holder 210 are opposite to the magnetic poles of the magnetic element 350 opposite to the needle holder 210, thereby applying a magnetic attraction force to the magnetic element 350, causing the limiting end 311 of the limiting member 310 to separate from the receiving groove 213. When the insulin pen is in operation, the magnetic pole of the magnetic force generating component 340 facing the needle holder 210 is the same as the magnetic pole of the magnetic component 350 facing away from the needle holder 210, so as to apply a repulsive force to the magnetic component 350, causing the limiting end 311 of the limiting component 310 to engage with the receiving groove 213.

[0072] Specifically, the limiting member 310 is disposed within the moving channel 321, and a magnetic element 350 is provided at the end of the limiting member 310 facing away from the needle holder 210. The limiting member 310 is an elongated magnetic structure, with the limiting end 311 designed as a protrusion facing towards the needle holder 210. The limiting member 310 can slide axially within the moving channel 321, engaging or disengaging with the receiving groove 213 through internal magnetic force or mechanical mechanism. The magnetic force generating assembly 340 is disposed on the side of the connecting member 320 facing away from the needle holder 210, and its magnetic pole position is opposite to the magnetic element 350 at the end of the limiting member 310. The magnetic pole direction of the magnetic force generating assembly 340 can be controlled to change, so as to apply magnetic attraction or repulsion to the magnetic element 350 under different working conditions.

[0073] Taking the magnetic force generating component 340 as an electromagnet as an example, when the magnetic force generating component 340 is an electromagnet, the control and reversal of its magnetic pole direction is achieved by changing the direction of the current in the electromagnet. The basic principle of an electromagnet is to generate a magnetic field through current, and the direction of the magnetic field depends on the direction of the current flow. An electromagnet consists of a wire winding wrapped around an iron core. When current flows through the winding, the iron core is magnetized, generating a magnetic field with a clearly defined north and south pole. By controlling the direction of the current flowing through the winding, the polarity of the generated magnetic field can be controlled. That is, changing the direction of the current will reverse the north and south poles of the electromagnet.

[0074] To facilitate the switching of the electromagnet's pole direction, the insulin pen may also include a control circuit or microcontroller (not shown) responsible for receiving user commands. The control circuit is connected to the electromagnet and switches the direction of the current based on user actions, such as pressing button 600. For example, when the device needs to enter working mode, the control circuit adjusts the current direction to generate a pole that repels the magnetic element 350. Conversely, when the needle holder 210 needs to be released for maintenance or the needle tube 220 needs to be replaced, the control circuit switches the current direction to generate a pole that attracts the magnetic element 350.

[0075] When the injection pen needs to fix the needle holder 210 (i.e., in working state), the control circuit makes the magnetic pole generated by the electromagnet the same as the magnetic pole of the magnetic component 350. Since like poles repel each other, this will push the limiting component 310 to make its limiting end 311 engage in the receiving groove 213 of the needle holder 210, thereby locking the needle holder 210.

[0076] When it is necessary to release the needle holder 210 from the syringe body 100 (i.e., in the non-working state), the control circuit reverses the current direction, so that the magnetic pole generated by the electromagnet is opposite to the magnetic pole of the magnetic component 350, thereby attracting the limiting component 310 to move, so that the limiting end 311 is disengaged from the receiving groove 213.

[0077] Through the above design, the insulin pen can achieve efficient automatic control while ensuring fast and safe operation, thus adapting to different usage scenarios and operational needs.

[0078] Please see Figures 2 to 5 In order to enable the limiting end 311 of the limiting member 310 to quickly and easily snap into the receiving groove 213 on the outer surface of the needle holder 210 when installing the injection assembly 200, the limiting mechanism 300 further includes a driving assembly 360. The driving assembly 360 includes a stator 361 and a rotor 362. The stator 361 is disposed at the opening 110 of the syringe body 100. The rotor 362 is connected to the stator 361 in a controlled rotation manner. The end of the rotor 362 facing away from the stator 361 is the driving end 3621. The driving assembly 360 is disposed at the opening 110 of the syringe body 100, and the driving end 3621 is connected to the connector 320 to drive the connector 320 to rotate around the needle holder 210.

[0079] Specifically, the stator 361 of the drive assembly 360 is fixedly sleeved on the outside of the opening 110 of the syringe body 100. The connector 320 is rotatably sleeved at the opening 110. The connector 320 is typically an annular or bushing structure with an internal sliding or rotating mechanism, allowing it to rotate around the needle holder 210. This connector 320 supports and guides the limiting member 310, ensuring it can accurately engage with the receiving groove 213 of the needle holder 210. The stator 361 is located at the opening 110 of the syringe body 100. The stator 361 is the fixed part of the motor, typically containing an electromagnetic coil, fixed within the structure of the syringe body 100, and used to generate rotational force. The rotor 362 is rotatably connected to the stator 361, with the end of the rotor 362 facing away from the stator 361 being the drive end 3621. The rotor 362 is the rotating part of the motor, driven by the electromagnetic force generated by the stator 361, achieving rotational movement. The drive end 3621 is connected to the connector 320, which drives the connector 320 to rotate around the needle holder 210. This design allows the position of the connector 320 to be directly controlled by the power of the motor, ensuring that the limiting end 311 of the limiting member 310 can quickly and easily snap into the receiving groove 213 of the needle holder 210.

[0080] This embodiment, by integrating a motor drive system, not only improves the positioning accuracy and operating speed of the components, but also enhances the convenience of user operation and the overall reliability of the device. When the insulin pen is ready for injection, the drive assembly 360 ensures that the limiting member 310 accurately and quickly positions and locks the needle hub 210, thereby guaranteeing the safety and efficiency of the injection process.

[0081] Furthermore, let's take the drive component 360 as an example of a printed circuit board (PCB) motor. A PCB motor is a type of motor design where components such as the stator 361 and the rotor 362 coils are manufactured using printed circuit board (PCB) technology. These motors are typically thinner and lighter than traditional motors and can be precisely integrated into electronic devices. Below is a detailed introduction to the working principle and structure of a PCB motor:

[0082] In PCB motors, the stator 361 is not a traditional combination of iron core and coils; instead, electromagnetic coils are printed directly on the PCB. These coils are designed with specific patterns and layers to generate a sufficient magnetic field. The PCB of the stator 361 can be designed as a multi-layer structure, with electrical wires printed on each layer, forming a complex circuit and coil layout to optimize the generation and distribution of the magnetic field.

[0083] The rotor 362 can optionally contain permanent magnets and be mounted on the rotating shaft. The rotor 362 can be a conventional circular shape or any shape designed for a specific application. In some designs, the rotor 362 may also be fabricated using PCB technology, especially in applications requiring a very thin overall device.

[0084] When current flows through the printed coils of stator 361, a magnetic field is generated around the coils. The layout of these coils and the direction of the current determine the shape and direction of the magnetic field. The motor control system (not shown in the figure, typically a microcontroller or dedicated driver IC) controls the current flowing through the coils, including its magnitude and direction, thereby controlling the nature of the magnetic field.

[0085] The magnetic field generated by the stator 361 interacts with the permanent magnet material on the rotor 362, producing torque and driving the rotor 362 to rotate. By changing the direction and magnitude of the current, the speed and position of the rotor 362 can be precisely controlled, achieving precise motion control.

[0086] PCB motors are particularly useful in applications requiring miniaturization, high integration, and specific form factors, such as in advanced medical devices, wearable devices, and precision instruments. The design and implementation of such motors provides an effective way to simplify device structure while maintaining high performance.

[0087] It should be noted that when the limiting end 311 of the limiting member 310 is engaged with the receiving groove 213, the force of the rotor 362 driving the connecting member 320 to rotate cannot overcome the resistance when the limiting end 311 of the limiting member 310 is engaged with the receiving groove 213. Only when the limiting end 311 is removed from the receiving groove 213 can the connecting member 320 continue to rotate.

[0088] Please see Figures 4 to 5The limiting mechanism 300 also includes a housing 370, which consists of a base 371 and a rotating body 372. The base 371 is basically a disc, and a stator 361 is mounted on the disc. A circular hole is provided at the center of the disc. It can be understood that a circular hole is also provided at the center of the stator 361 so that the opening 110 of the syringe body 100 can pass through. The disc is fitted into the opening 110 of the syringe body 100 through the circular hole. The rotor 362 is fitted onto the outlet 110 of the syringe body 100 in a rotating manner. The rotor 362 is located on the side away from the stator 361 along its own thickness direction. The device has a drive tube, and the end of the drive tube opposite to the stator 361 is the drive end 3621. The drive end 3621 is splinedly connected to the connector 320. The structure of the rotating body 372 is similar to that of the base 371. The rotating body 372 is fixedly sleeved on the outside of the drive tube so as to rotate synchronously with the rotor 362. A baffle for shielding the stator 361 is constructed near the base 371 on the rotating body 372. The periphery of the disc facing the baffle is constructed along its own thickness direction towards the baffle to contact the baffle. When the rotating body 372 rotates, it slides with the base 371 to form protection for the drive assembly 360.

[0089] To ensure that the needle hub 210, connected to the opening 110 of the syringe body 100, can smoothly fall out of the opening 110 when the limiting end 311 separates from the receiving groove 213, the insulin pen also includes a drug reservoir 400, which includes a liquid storage cavity 410 and a drug outlet 420 communicating with the liquid storage cavity 410. The syringe body 100 also includes a receiving space 120 communicating with the opening 110, the drug reservoir 400 is disposed within the receiving space 120, and the drug outlet 420 is inserted into the opening 110, with the needle hub 210 inserted into the drug outlet 420. The inner sidewall of the drug outlet 420 is constructed as a first conical surface 421, and the outer peripheral side of the insertion portion of the needle hub 210 and the drug outlet 420 is constructed as a second conical surface 212 adapted to the first conical surface 421 of the inner sidewall of the drug outlet 420. A gap is provided between the side of the needle holder 210 facing the connector 320 and the side of the connector 320 facing the needle holder 210.

[0090] Specifically, the needle hub 210 has a cylindrical structure, and its outer surface is constructed as a second conical surface 212, designed to mate with the first conical surface 421 of the inner sidewall of the drug outlet 420. A receiving groove 213 is formed on the second conical surface 212. A gap is provided between the side of the needle hub 210 facing the connector 320 and the side of the connector 320 facing the needle hub 210, allowing the needle hub 210 to smoothly fall from the opening 110 when the limiting end 311 separates from the receiving groove 213. The drug storage container 400 is disposed within the receiving space 120 of the syringe body 100, and the drug outlet 420 is inserted into the opening 110 and connected to the needle hub 210. The inner wall of the drug outlet 420 is constructed as a first conical surface 421, which is adapted to the second conical surface 212 of the needle seat 210, ensuring that the liquid can be smoothly transferred from the liquid storage cavity 410 to the needle seat 210 through the drug outlet 420, and providing a good seal for the connecting section.

[0091] Through the above design, the insulin pen not only ensures smooth delivery and accurate injection of the medication, but also allows the needle hub 210 to automatically detach from the syringe body 100 when necessary, facilitating replacement or maintenance. The tapered fit between the dispensing port 420 and the needle hub 210 enhances the stability of the connection, while simplifying the engagement and disengagement of components, improving ease of use and safety.

[0092] The above description in this specification is merely illustrative of the present invention. Those skilled in the art to which this invention pertains may make various modifications or additions to the described specific embodiments or use similar methods to replace them, as long as they do not depart from the content of this specification or exceed the scope defined in the claims, all of which shall fall within the protection scope of this invention.

Claims

1. An insulin injection pen, characterized in that, include: The syringe body, including the opening; Injection assembly, including: A needle hub, including a receiving cavity, wherein the needle hub is inserted into the opening; A needle tube, one end of which is connected to the needle hub, and the needle tube communicates with the receiving cavity; The limiting mechanism includes: A limiting member is provided at the opening, and the limiting member is movable under control. When the insulin pen is in working condition, the limiting member is connected to the needle hub, so that the needle hub is connected to the syringe body, and the injection assembly is restricted to the opening of the syringe body; when the insulin pen is not in working condition, the limiting member is separated from the syringe body.

2. The insulin injection pen according to claim 1, characterized in that: The limiting mechanism also includes a connector, which is disposed at the opening and has a moving channel on the inner wall facing the needle seat. The outer surface of the needle holder is provided with a receiving groove facing the inner wall of the opening; The limiting member is disposed within the moving channel, and the limiting member includes a limiting end, which is disposed toward the needle seat. When the insulin pen is in working condition, the limiting end of the limiting member engages with the receiving groove on the outer surface of the needle hub; when the insulin pen is not in working condition, the limiting end of the limiting member separates from the receiving groove.

3. An insulin injection pen according to claim 2, characterized in that: The limiting component is a magnetically conductive component; The limiting mechanism further includes: An elastic element is disposed within the moving channel. One end of the elastic element abuts against the inner wall of the moving channel, and the other end of the elastic element abuts against the limiting element, so as to provide elastic force towards the needle seat for the limiting element, and so that the limiting end of the limiting element is exposed in the opening. A magnetic force generating component is disposed on the side of the connector away from the needle hub, and the position of the magnetic force generating component is opposite to the limiting member, so as to apply a magnetic attraction force away from the needle hub to the limiting member when the insulin pen is in a non-working state, so as to separate the limiting end from the receiving groove.

4. An insulin injection pen according to claim 2, characterized in that: The end of the limiting member that faces away from the needle seat is provided with a magnetic element; The limiting mechanism further includes: A magnetic force generating component is disposed on the side of the connector away from the needle seat. The magnetic pole position of the magnetic force generating component is oriented opposite to the magnetic element at the end of the limiting component, and the magnetic pole direction of the magnetic force generating component is controlled to change. When the insulin pen is in a non-working state, the magnetic pole of the magnetic force generating component facing the needle hub is opposite to the magnetic pole of the magnetic element facing away from the needle hub, so as to apply a magnetic attraction force to the magnetic element and separate the limiting end of the limiting member from the receiving groove; when the insulin pen is in a working state, the magnetic pole of the magnetic force generating component facing the needle hub is the same as the magnetic pole of the magnetic element facing away from the needle hub, so as to apply a repulsive force to the magnetic element and make the limiting end of the limiting member engage with the receiving groove.

5. An insulin pen according to any one of claims 2-4, characterized in that: The limiting mechanism further includes: A drive assembly, including a controllable rotating drive end, is disposed at the opening of the syringe body, and the drive end is connected to the connector to drive the connector to rotate around the needle hub.

6. An insulin injection pen according to claim 5, characterized in that: The driving component also includes: A stator is disposed at the opening in the syringe body; The rotor is connected to the stator in a controlled rotation manner, and the driving end is the end of the rotor that is away from the stator.

7. An insulin pen according to any one of claims 2-4, characterized in that: The insulin pen also includes: A drug storage container, the drug storage container including a liquid storage cavity and a drug outlet communicating with the liquid storage cavity; The syringe body also includes a receiving space communicating with the opening, the drug storage container is disposed in the receiving space, the drug outlet is inserted into the opening, and the needle hub is inserted into the drug outlet.

8. An insulin injection pen according to claim 7, characterized in that, The inner wall of the drug outlet is constructed as a first conical surface, and the outer periphery of the insertion portion of the needle seat and the drug outlet is constructed as a second conical surface that matches the first conical surface of the inner wall of the drug outlet.

9. An insulin injection pen according to claim 8, characterized in that, A gap is provided between the side of the needle holder facing the connector and the side of the connector facing the needle holder.

Images